CTLA4 and melanoma: Anti-PD-1 agents (nivolumab and pembrolizumab), anti-CTLA-4 therapy (ipilimumab), and combination regimens involving both checkpoints (nivolumab–ipilimumab) have become approved treatment options for melanoma, driven by the promising clinical outcomes of immune checkpoint inhibition.